EUCTR2016-004039-19-ES进行中（未招募）1 期
Phase II multicenter trial of palbociclib in second line of advanced sarcomas with CDK4 overexpression. - PalboSarc
Grupo Español de Investigación en Sarcomas (GEIS)0 个研究点开始时间: 2016年12月27日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1)Over-expression of CDK4 (mRNA expression) and a low-to-normal p16 expression (mRNA expression) measured in paraffin embedded tumor samples at study entry.
- •2)ECOG 0-1 at enrollment.
- •3)Diagnosis of soft tissue sarcoma or osteosarcoma (in both cases with metastasis or locally advanced, unresectable).
- •4)Disease progression documented within 6 months prior to study entry.
- •5)Patients must have the following laboratory results:
- •ANC = 1,500/mm3 (1.5 x 109/L);
- •Platelets = 100,000/mm3 (100 x 109/L);
- •Hemoglobin = 9 g/dL (90 g/L);
- •Serum creatinine = 1.5 x ULN or estimated creatinine clearance = 60 mL/min;
- •Total serum bilirubin = 1.5 x ULN (= 3.0 x ULN if Gilbert’s disease);
- •AST and/or ALT = 3 x ULN (= 5.0 x ULN if liver metastases present);
- •Alkaline phosphatase = 2.5 x ULN (= 5.0 x ULN if bone or hepatic metastasis present);
- •6)Patients must have signed written informed consent to participate in the clinical study, and to provide at least two paraffin embedded tumor blocks for the molecular analyses at screening stage.
- •7)Biopsy at baseline if there are no archived tumor samples obtained within 3 months prior to treatment initiation.
- •8)Patients must have received standard treatments for at least one or two lines for advanced disease.
- •9)Age between 18 and 80 years (both ages included).
- •10)Measurable disease according to RECIST 1.1 criteria.
- •11)All patients (men and women) in fertile age must use an effective contraception method during the entire treatment with palbociclib and for at least 90 days after the last dose. Pregnancy must be ruled out through urine or blood test (negative pregnancy test) for the inclusion in the study. Men must be informed to consider spermatic preservation before treatment initiation due to infertility risks.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 23
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •1)Previous treatment with any anti CDK4 or immune checkpoint inhibitor.
- •2)Diagnosis of Ewing sarcoma or rhabdomyosarcoma.
- •3)Diagnosis of well differentiated/dedifferentiated liposarcoma.
- •4)Patients irradiated on the only target lesion available.
- •5)Patients having received more than two lines for advanced disease.
- •6)History of other neoplastic disease with the exception of basal cell carcinoma or in situ cervical cancer adequately treated.
- •7)Serious cardiovascular disease (NYHA >= 2)
- •8)Grade 3 or superior toxicity according to CTCAE 4.0 if the investigator considers this can significantly interfere in the toxicity of the drug under study.
- •9)Patients not recovered from a previous toxicity to at least CTCAE Grade 1 due to prior chemotherapy, radioactive, or biological cancer therapy (including monoclonal antibodies).
- •10)Patients not recovered from minor or major surgery or having undergone a major surgery within the last 4 weeks prior to initiation of study treatment.
- •11)Central nervous system metastasis.
- •12)Pregnant or breastfeeding patients, or those expecting to conceive or father children within the projected duration of treatment.
- •13)Foods or drugs known as CYP3A4 inhibitors/inducers; CYP3A4 substrates with narrow therapeutic windows, or known to prolong QTc interval.
- •14)Major surgery, chemotherapy, radiotherapy, any agent under investigation, or other antineoplastic therapy within 4 weeks prior to inclusion. Patients having received a previous radiotherapy =25% of bone marrow are not eligible, regardless of when it was received.
- •15)QTc > 480 ms; personal or family history of long or short QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsades de Pointes (TdP).
- •16)Any of the following situations within 6 months prior to study drug administration: myocardial infarction, serious/unstable angina, current cardiac dysrhythmias Grade = 2 NCI-CTCAE version 4.0, atrial fibrillation of any grade, bypass graft in coronary/peripheral artery, symptomatic congestive cardiac failure, cerebrovascular accident including transient ischemic attack, or symptomatic pulmonary embolism.
- •17)Known hypersensitivity to any PD 0332991 or excipients.
- •18)Active or recent suicide attempt or behavior.
研究者
相似试验
招募中
1 期
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Solid TumorsCTRI/2022/04/042263Pfizer Inc
进行中（未招募）
2 期
Phase II Palbociclib +Ibrutinib in Mantle Cell LymphomaB Cell LymphomaMantle Cell LymphomaNCT03478514Alliance Foundation Trials, LLC.39
已完成
2 期
Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB PreservedOligodendrogliomaOligoastrocytomaNCT02530320Grupo Español de Investigación en Neurooncología34
招募中
2 期
High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)Breast CancerNCT04247633Samsung Medical Center578
进行中（未招募）
2 期
Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated LiposarcomaNCT05694871Alliance for Clinical Trials in Oncology77